NIH-funded research R01 grant

Investigating how immune cells affect blood vessel health in high blood pressure.

Official title: Stromal interaction molecule 1, immune cells, and vascular pathology in established hypertension

Funded at Old Dominion University · NIH-11123676 · Data updated 2026-11-12

This study is looking at how certain immune cells might affect blood vessel health in people with high blood pressure, and it hopes to find new ways to improve their condition by testing healthy immune cells in animal models.

More Hypertension research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionOld Dominion University
NIH-funded
Lab location1 site (Norfolk, United States)
Project startJuly 1, 2020
Project endJune 30, 2025
Funding year2023
Award (this year)$16,879
NIH project number6R01HL151616-05
Project IDNIH-11123676 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals with established hypertension who have not responded well to current treatments.

Less likely to help

Patients with normal blood pressure or those whose hypertension is well-controlled may not benefit from this research.

What this research studies

This research focuses on understanding the mechanisms that lead to vascular problems in patients with established hypertension. It explores how certain immune cells, particularly Treg cells, interact with blood vessels and how their dysfunction may contribute to high blood pressure complications. By studying the role of stromal interaction molecule 1 (STIM1) in these immune cells, the research aims to identify potential targets for new treatments that could improve vascular function and structure in hypertensive patients. The approach includes transferring healthy immune cells into animal models to observe changes in vascular health.

Why it matters

Potential benefit: If successful, this research could lead to new therapies that improve blood vessel function and reduce complications for patients with hypertension.

How similar studies have gone: While the specific approach of targeting STIM1 in Treg cells is novel, similar studies have shown promise in improving vascular health through immune modulation.

Where this research is happening

  • Old Dominion University
    Norfolk, United States
    Active

Researchers

  • Principal investigator: Matrougui, Khalid — Old Dominion University
  • Study coordinator: Matrougui, Khalid

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.